In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 0.05 a new company low.

Within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Cyclo Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 2807 to 4275.

Explain Quick Ratio?
How much Cash & cash equivalents CYTH�s has?
What are CYTH�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CYTH Quick Ratio	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3
Y / Y Current Liabilities Change	183.14 %	57.2 %	31.37 %	165.32 %	130.11 %
Y / Y Cash & cash equivalent Change	-48.5 %	33.31 %	227.26 %	499.1 %	-58 %
Quick Ratio MRQ	0.05	0.12	0.51	1	0.27
CYTH's Total Ranking	# 4275	# 2807	# 1466	# 1056	# 2836
Seq. Current Liabilities Change	95.71 %	62.26 %	-36.23 %	39.83 %	8.66 %
Seq. Cash & cash equivalent Change	-17.28 %	-62.54 %	-67.61 %	413.13 %	114.13 %

Quick Ratio third quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 157
Healthcare Sector	# 939
Overall Market	# 4275

Quick Ratio Statistics
High	Average	Low
10.58	2.22	0.05
(Sep 30 2014)		(Sep 30 2024)

Financial Statements
Cyclo Therapeutics Inc 's Current Liabilities	$ 19 Millions	Visit CYTH's Balance sheet
Cyclo Therapeutics Inc 's Cash & cash equivalent	$ 1 Millions	Visit CYTH's Balance sheet
Source of CYTH's Sales		Visit CYTH's Sales by Geography

Cumulative Cyclo Therapeutics Inc 's Quick Ratio

CYTH's Quick Ratio for the trailling 12 Months

CYTH Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	110.11 %	84.98 %	115.13 %	133.54 %	77.44 %
Y / Y Cash & cash equivalent TTM Growth	180.11 %	99.8 %	4.81 %	-48.95 %	-87.29 %
Quick Ratio TTM	0.33	0.48	0.54	0.49	0.25
Total Ranking TTM	# 4023	# 3007	# 1388	# 2787	# 4036
Seq. Current Liabilities TTM Growth	38.66 %	12.5 %	5.33 %	27.87 %	22.08 %
Seq. Cash & cash equivalent TTM Growth	-5.76 %	1.88 %	16.24 %	150.98 %	-32.78 %

Quick ratio ranking by company, industry and sector >> Back to CYTH Financial Strength Comparisons >> Go to Compare CYTH Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2024 to $18.70 millions, cumulative Quick Ratio decreased to 0.33 below the Cyclo Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 160 other companies have achieved higher Quick Ratio than Cyclo Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3007 to 4023.

Explain Quick Ratio?
How much Cash & cash equivalents CYTH�s has?
What are CYTH�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 161
Healthcare Sector	# 996
Within the Market	# 4023

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.72	1.66	0.25
(Dec 31 2021)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2024 MRQ Cash & cash equivalent	Sep 30 2024 MRQ Current Liabilities
Redwoods Acquisition Corp	0.05	$ 0.051 Millions	$ 0.982 Millions
Alvotech	0.05	$ 51.428 Millions	$ 1,035.882 Millions
Cyclo Therapeutics Inc	0.05	$ 0.928 Millions	$ 18.700 Millions
Exozymes Inc	0.04	$ 0.234 Millions	$ 5.802 Millions
Peak Bio Inc	0.04	$ 0.862 Millions	$ 22.398 Millions
Ladrx Corporation	0.03	$ 0.057 Millions	$ 1.829 Millions
Brainstorm Cell Therapeutics inc	0.02	$ 0.168 Millions	$ 7.082 Millions
Zivo Bioscience Inc	0.01	$ 0.037 Millions	$ 2.579 Millions
Pelthos Therapeutics Inc	0.01	$ 0.040 Millions	$ 3.567 Millions

Date modified: 2026-06-22T14:32:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.